Understand the source comparison
Adamax Stacking Guide: Dosing Comparison Table
The following table compares three evidence-supported Adamax stacking protocols by mechanism, daily injection burden, and expected fat mass reduction based on published peptide monotherapy data and observed synergistic effects in metabolic research. Adamax + I
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares three evidence-supported Adamax stacking protocols by mechanism, daily injection burden, and expected fat mass reduction based on published peptide monotherapy data and observed synergistic effects in metabolic research.
- Adamax + Ipamorelin + AOD9604
- MC4R activation + GH secretion + beta-3 adrenergic lipolysis
- 3 (2 Adamax, 1 combined GHS/AOD)
- Moderate (MC4R-mediated)
- High (overlapping pathways)
- 8–12% body fat
- Best all-around stack for lipolysis without cardiovascular burden. All three compounds have established safety profiles and non-overlapping side effects
- Adamax + Tesofensine
- MC4R activation + monoamine reuptake inhibition
- 2 (Adamax only; Tesofensine oral)
- Very High (dual central pathways)
- Very High (10–15% metabolic rate increase)
- 10–15% body fat
- Highest efficacy for appetite-driven models, but requires cardiovascular monitoring. Tesofensine elevates heart rate 5–10 bpm in most subjects
- Adamax + MOTS-C + 5-Amino-1MQ
- MC4R activation + AMPK activation + NAD+ preservation
- 2 (1 Adamax + MOTS-C combined, 1 Adamax solo; 5-Amino oral)
- Low (MC4R only)
- Moderate (substrate shift, not rate increase)
- 6–10% body fat
- Ideal for metabolic efficiency research where caloric intake is controlled. Emphasizes mitochondrial function over appetite suppression
- Fat mass reduction estimates assume controlled caloric intake at 10–15% below maintenance and consistent dosing adherence over 12 weeks. Actual results vary based on baseline body composition, dietary substrate composition, and activity level. The Adamax + Tesofensine stack shows the highest potential reduction but carries cardiovascular monitoring requirements that the GHS-based stack does not.